2017
High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence
Wasserman BE, Carvajal-Hausdorf DE, Ho K, Wong W, Wu N, Chu VC, Lai EW, Weidler JM, Bates M, Neumeister V, Rimm DL. High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence. Laboratory Investigation 2017, 97: 1521-1526. PMID: 28892092, PMCID: PMC5711560, DOI: 10.1038/labinvest.2017.93.Peer-Reviewed Original ResearchConceptsInvasive breast cancerBreast cancerQuantitative immunofluorescenceRT-qPCRFormalin-fixed paraffin-embedded tissue blocksRT-qPCR assaysEquivocal categoryReal-time quantitative reverse transcription polymerase chain reactionHER2 receptor statusQuantitative reverse transcription polymerase chain reactionParaffin-embedded tissue blocksReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionIHC/FISHMRNA measurementsAssessment of HER2Low-resource settingsReceptor statusPolymerase chain reactionPathology reportsCT cutsSingle-use cartridgeResource settingsHER2 mRNATissue blocks
2014
In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients
Vassilakopoulou M, Togun T, Dafni U, Cheng H, Bordeaux J, Neumeister VM, Bobos M, Pentheroudakis G, Skarlos DV, Pectasides D, Kotoula V, Fountzilas G, Rimm DL, Psyrri A. In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients. PLOS ONE 2014, 9: e99131. PMID: 24968015, PMCID: PMC4072595, DOI: 10.1371/journal.pone.0099131.Peer-Reviewed Original ResearchConceptsBreast cancer patientsMetastatic breast cancer patientsFISH HER2Cancer patientsHER2 mRNAPrognostic factorsTrastuzumab-treated metastatic breast cancer patientsMultivariate Cox regression modelECD HER2Log rank pMetastatic breast cancerStrong prognostic factorCox regression modelKaplan-Meier estimatesHER2 mRNA levelsHER2-ICDChemotherapy regimensMetastatic cohortTrastuzumab treatmentBreast cancerTissue microarrayMRNA statusPerformance of markersHER2 receptorPredictive value
2012
In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients.
Vassilakopoulou M, Bordeaux J, Neumeister V, Cheng H, Schalper K, Skarlos D, Pectasides D, Pavlidis N, Koutras A, Linardou H, Razis E, Bobos M, Kotoula V, Rimm D, Fountzilas G, Psyrri A. In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients. Journal Of Clinical Oncology 2012, 30: 573-573. DOI: 10.1200/jco.2012.30.15_suppl.573.Peer-Reviewed Original ResearchBreast cancer patientsMetastatic breast cancer patientsCancer patientsHER2 mRNA levelsHER2 mRNAHistological gradeTrastuzumab-treated metastatic breast cancer patientsMultivariate analysisCox proportional hazards modelHormone receptor statusMetastatic breast cancerKaplan-Meier analysisOverall survival timeMRNA levelsProportional hazards modelHER2 extracellular domainAssessment of HER2Extracellular domainTrastuzumab initiationChemotherapy regimensPrimary endpointReceptor statusTrastuzumab therapyMetastatic cohortTrastuzumab treatment